论文部分内容阅读
目的探析曲美他嗪辅助标准抗心衰药物在慢性心力衰竭中的疗效。方法选取我院2013年11月~2015年11月收治的慢性心力衰竭患者72例作为研究对象,按数字法分为研究组和对照组,各36例。其中对照组采用标准抗心衰药物治疗,而研究组则增加曲美他嗪治疗,并对比两组的疗效。结果研究组心功能改善的总有效率为91.67%,明显优于对照组的69.44%,差异有统计学意义(x2=5.67,P<0.05);6 min步行距离、心率水平还有左心室射血分数改善疗效均优于对照组,差异有统计学意义(P<0.05)。结论利用曲美他嗪辅助标准抗心衰药物对慢性心力衰竭患者实行临床治疗,可以对患者的心功能起到良好的改善作用,疗效显著,值得推广。
Objective To investigate the efficacy of trimetazidine-assisted standard anti-heart failure drugs in chronic heart failure. Methods Seventy-two patients with chronic heart failure who were admitted to our hospital from November 2013 to November 2015 were selected as study objects and divided into study group and control group according to the digital method, with 36 cases in each group. The control group was treated with standard anti-heart failure drugs, while the study group was increased trimetazidine treatment, and compared the efficacy of the two groups. Results The total effective rate of improvement of cardiac function in study group was 91.67%, which was significantly better than that of control group (69.44%), the difference was statistically significant (x2 = 5.67, P <0.05); 6 min walking distance, heart rate and left ventricular ejection The improvement of blood test results were better than the control group, the difference was statistically significant (P <0.05). Conclusion Trimetazidine-assisted standard anti-heart failure drugs for clinical treatment of patients with chronic heart failure can play a good role in improving the patient’s cardiac function, the effect is significant, it is worth promoting.